C-myc oncogene expression in human melanoma and its relationship with tumour antigenicity

European Journal of Surgical Oncology

Volumn 22, Issue 4, 1996, Pages 342-346

  Grover, R ^a   Ross, D A ^a   Richman, P I ^a   Robinson, B ^a   Wilson, G D ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Antigen; Melanoma; Oncogene

Indexed keywords

HLA ANTIGEN CLASS 1; MELANOMA ANTIGEN; ONCOPROTEIN;

ANTIGENICITY; ARTICLE; CELL SURFACE; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MELANOMA; METASTASIS; MOLECULAR RECOGNITION; ONCOGENE C MYC; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0029743362     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(96)90154-7     Document Type: Article

References (14)

1. Gaugler B, Van den Eynde B, Van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921-30.
2. Nudelman E, Hakomori SI, Kannagi R, Levery S. Characterisation of a human melanoma associated antigen identified by a monoclonal antibody. J Biol Chem 1982; 257: 12752-6.
3. Tanaka K, Yoshioka A, Bieberich C. Role of the major histocompatability complex class I antigens in tumour growth and metastasis. Ann Rev Immunol 1988; 6: 359-80.
4. Van Duinen SG, Ruiter DJ, Broeker EB, Velde EA, Sorg C, Welvaart, Ferrone S. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988; 48: 1019-25.
5. Versteeg R, Noordermeer IA, Kruse-Walters M. C-myc down regulates class I HLA expression in human melanomas. EMBO J 1988; 7: 1023-9.
6. Ross DA, Wilson GD. C-myc oncoprotein expression acts as a prognostic marker in high risk malignant melanoma. Br J Cancer 1994; 69(SXXI): 55.
7. Hedley DW, Freidlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-5.
8. Ruiter DJ, Mattijssen V, Broeker EB, Ferrone S. MHC antigens in human melanoma. Semin Cancer Biol 1991; 2: 35-45.
9. Marincola FM, Shamamian P, Alexander RB, Gnarra JR. Loss of HLA haplotype and B locus down regulation in melanoma cell lines. J Immunol 1994; 153: 1225-37.
10. Hui KM, Sim TF, Foo TT, Oei AA. Tumour rejection mediated by transfection with class I histocompatability gene. J Immunol 1989; 11: 3835-43.
11. Bernards R, Dessain SK, Weinberg RA. N-myc amplification causes down modulation of MHC class I antigen expresion in neuroblastoma. Cell 1986; 47: 667-74.
12. Peltenburg LTC, Schrier P. Transcriptional suppression of HLA-B expression is mediated through the core promoter elements. Immunogenetics 1994; 40: 54-61.
13. Evan GI, Littlewood TD. The role of c-myc in cell growth. Curr Opin Genetics Devel 1993; 3: 44-9.
14. Colomer R, Lupu R, Bacus CC, Gelmann EP, erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 1994; 70: 819-25.